Curative, platinum-based cytoxic drug therapy in a renal transplant recipient with metastatic testicular cancer
| Autor: | Andrew W. Osiason, Robert J. Polackwich |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Cisplatin
Cancer Research medicine.medical_specialty Chemotherapy Kidney business.industry medicine.medical_treatment Urology Induction chemotherapy urologic and male genital diseases Bleomycin Surgery Vinblastine chemistry.chemical_compound Pharmacotherapy medicine.anatomical_structure Oncology chemistry medicine Vinblastine Sulfate business medicine.drug |
| Zdroj: | Cancer. 58:850-851 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/1097-0142(19860815)58:4<850::aid-cncr2820580407>3.0.co;2-r |
| Popis: | Since June 1979, the authors have had the opportunity to treat a renal homograph recipient who developed primary embryonal cell testicular carcinoma with retroperitoneal and pulmonary metastases. This patient was treated with an induction chemotherapy protocol of vinblastine sulfate, bleomycin, and cisplatin and has remained free of disease through June 1985, without loss of his renal homograph. Cisplatin-based cytoxic drug therapy can be delivered safely to a renal transplant recipient without causing kidney damage, and, in this case, achieved a cure of metastatic testicular cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text